Pityriasis Lichenoides Chronica, Role of Streptococcal Infection and Azithromycin

• Status: Unknown status
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary outcome:

The primary outcome at end of study (EOS) is to compare the therapeutic efficacy of Azithromycin in the treatment of pityriasis lichenoides chronica (PLC) with that of a well-documented line of therapy namely narrow band ultra violet B (nbUVB).

Secondary outcomes:

1. To identify the possibility of streptococcal throat infection as a possible underlying etiology in PLC.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

1. Patients with classic papular eruption of PLC (scaly erythematous papules with mica-like scales) with diagnosis documented histopathologically with or without associated hypopigmented lesions

2. Age: > 6 years

3. Both sexes.

Exclusion Criteria:

1. Patients presenting with only hypopigmented macules whom their skin biopsy revealed PLC.

2. Patients with hypopigmented lesions that reveal mycosis fungoides pathologically.

3. Patients with PLC associated with classic MF.

4. Patients with known absolute contraindications to NB-UVB.

5. Patients with impaired liver and/or kidney functions.

6. Patients with history of any heart disease.

7. Patients with known hypersensitivity to Azithromycin

-